Literature DB >> 9630338

Endogenous orphanin FQ: evidence for a role in the modulation of electroacupuncture analgesia and the development of tolerance to analgesia produced by morphine and electroacupuncture.

J H Tian1, W Zhang, Y Fang, W Xu, D K Grandy, J S Han.   

Abstract

1. Our previous work has demonstrated that exogenously administered orphanin FQ (OFQ) antagonizes morphine analgesia and electroacupuncture analgesia (EAA) in the brain and potentiates morphine analgesia and EAA in the spinal cord of the rat. In the present study we evaluated the role of endogenously released OFQ in the development of tolerance to morphine and electroacupuncture (EA) and the analgesia produced by electroacupuncture, by use of the IgG fraction of an anti-OFQ antibody (OFQ-Ab) microinjected into the rat central nervous system (CNS). 2. EAA was produced by stimulating rats at a frequency of 100 Hz. Rats were classified as either high responders (HR) or low responders (LR) based on the analgesic effects of EA. LRs could be converted into HRs by the intracerebroventricular (i.c.v.) microinjection of OFQ-Ab at both 1:1 and 1:10 dilutions but not 1:100. HRs could be changed into LRs by the intrathecal (i.t.) injection of OFQ-Ab at both 1:1 and 1:10 dilutions, but not 1:100. 3. Acute morphine tolerance was induced in rats by repeated subcutaneous (s.c.) injections of morphine (5 mg kg, every 2 h) for 16 h. When injected i.c.v. the OFQ-Ab (1:1 dilution) had no effect on the development of acute morphine tolerance. 4. Chronic morphine tolerance was produced in rats by repeated injection of morphine (5-60 mg kg, s.c., 3 x a day) for 6 days. I.c.v. injection of OFQ-Ab (1:1 dilution) reversed this type of morphine tolerance in rats by 50% (P < 0.01). 5. Acute tolerance to the analgesia produced by EA developed after 6 h of continuous (100 Hz, 3 mA) stimulation. This tolerance was almost completely reversed by the i.c.v. injection of OFQ-Ab (1:1 dilution) (P < 0.05). 6. Chronic tolerance to the analgesic effect of EA was produced by repeatedly administering increasing current (1, 2 and 3 mA, each lasting for 10 min, for a total of 30 min) at a frequency of 100 Hz once a day for 6 days. I.c.v. injection of OFQ-Ab (1:1 dilution) reversed this kind of tolerance by 50% (P < 0.01). 7. Together these results suggest that 100 Hz EA may enhance the release of endogenous OFQ in the CNS of the rat, which in turn may act to antagonize EA-produced analgesia in the brain but potentiate EA produced analgesia in the spinal cord. Therefore, OFQ appears to play an important role in the development of tolerance to the analgesic effects produced by EA. 8. The mechanisms underlying the development of acute morphine tolerance and chronic morphine tolerance appear to be different. Central OFQ may play an important role in the development of tolerance after chronic morphine administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630338      PMCID: PMC1565350          DOI: 10.1038/sj.bjp.0701788

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test.

Authors:  Xiaohong Chen; Ellen B Geller; Martin W Adler
Journal:  Eur J Pharmacol       Date:  2006-11-10       Impact factor: 4.432

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Electroacupuncture induces antihyperalgesic effect through endothelin-B receptor in the chronic phase of a mouse model of complex regional pain syndrome type I.

Authors:  Leidiane Mazzardo-Martins; Daiana Cristina Salm; Elisa C Winkelmann-Duarte; Júlia Koerich Ferreira; Daniela Dero Lüdtke; Kamilla Pamplona Frech; Luiz Augusto Oliveira Belmonte; Verônica Vargas Horewicz; Anna Paula Piovezan; Francisco José Cidral-Filho; Ari Ojeda Ocampo Moré; Daniel Fernandes Martins
Journal:  Pflugers Arch       Date:  2018-08-10       Impact factor: 3.657

4.  Orphanin FQ suppresses NMDA receptor-dependent long-term depression and depotentiation in hippocampal dentate gyrus.

Authors:  W Z Wei; C W Xie
Journal:  Learn Mem       Date:  1999 Sep-Oct       Impact factor: 2.460

5.  Effects of moxibustion on dynorphin and endomorphin in rats with chronic visceral hyperalgesia.

Authors:  Hui-Rong Liu; Li Qi; Lu-Yi Wu; Xiao-Peng Ma; Xiu-Di Qin; Wen-Yan Huang; Ming Dong; Huan-Gan Wu
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

6.  Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.

Authors:  G Calo'; R Guerrini; R Bigoni; A Rizzi; G Marzola; H Okawa; C Bianchi; D G Lambert; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

7.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

8.  Kainic acid down-regulates NOP receptor density and gene expression in human neuroblastoma SH-SY5Y cells.

Authors:  Rosalia Cannarsa; Daniela Landuzzi; Chiara Cavina; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2008-02-20       Impact factor: 3.444

9.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

10.  Electroacupuncture effects in a rat model of complete Freund's adjuvant-induced inflammatory pain: antinociceptive effects enhanced and tolerance development accelerated.

Authors:  Cheng Huang; Zhi-Qin Huang; Zhi-Ping Hu; Shao-Zu Jiang; Han-Ting Li; Ji-Sheng Han; You Wan
Journal:  Neurochem Res       Date:  2008-05-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.